A mother braiding her daughter’s hair by a window that looks out on a lake.

Get ahead of cancer with the Cancerguard™ test

Peace of mind starts with a single blood test that helps detect cancer, even aggressive and hard-to-find types, before symptoms appear.

  • For ages 50-84 with no known cancer in the last 3 years1
  • The Cancerguard test is designed to detect more than 50 cancer types and subtypes.2
  • Can detect cancers with no screening options that cause ~70% of cancer deaths1
  • Detected 1 in 3 early stage cancers in a clinical study1
  • $689, HSA/FSA eligible*
Request Cancerguard
$689, HSA/FSA eligible*

Peace of mind starts with a single blood test that helps detect cancer, even aggressive and hard-to-find types, before symptoms appear.

  • For ages 50-84 with no known cancer in the last 3 years1
  • The Cancerguard test is designed to detect more than 50 cancer types and subtypes.2
  • Can detect cancers with no screening options that cause ~70% of cancer deaths1
  • Detected 1 in 3 early stage cancers in a clinical study1
  • $689, HSA/FSA eligible*

Many cancers are detected too late to be effectively treated

Cancerguard is designed to complement standard cancer screening, and give you the early insight you need to make more confident decisions.
~70% of cancer deaths occur in cancers without screening options1
Only 4 out of dozens of cancers currently have screening guidelines3
Only 1 in 7 cancers are detected through screening, that’s just 14%‡,5

Helps find it early

Give yourself the best chance to fight cancer by finding it in its early stages — when it's easier to treat.

42%

reduction in stage IV cancer incidence with supplemental Cancerguard testing†

Helps find the most aggressive

Catch the deadliest and most aggressive cancers that often aren't diagnosed until symptoms appear.1

6+

Cancerguard helps detect hard-to-find cancer, including 6 of the deadliest cancers1

Helps find more cancers

Many cancers don’t have screening options. With a simple blood draw, Cancerguard helps detect multiple types of cancer that make up at least 80% of all cancer diagnoses in the US1 including:

  • Lung and bronchus
  • Breast‖
  • Colon and rectum
  • Uterus
  • Kidney
  • Head and neck
  • Pancreas
  • Prostate‖
  • Cervix
  • Bladder and urinary
  • Stomach
  • Esophagus
  • Liver and bile duct
  • Ovary
  • Anus
  • Thyroid
  • Vulva
  • Small intestine
  • Non-Hodgkins lymphoma
  • Testes

‖ The Cancerguard test is not indicated for breast and prostate cancer screening, however it may detect these cancers. The performance characteristics of additional cancer types that may be detected by the test is unknown. This test is not a replacement for existing recommended cancer screening or diagnostic modalities for cancer.

Is Cancerguard right for you?

Peace of mind starts with early detection

A close up of a man with a white beard.

Designed for those most likely to benefit.

Cancer status
No known cancer in the last 3 years
Recommended age
50-84
Cancer status
No known cancer in the last 3 years
Recommended age
50-84

You can also talk to your doctor to see if Cancerguard is right for you based on:

A woman with long gray hair smiling and lifting small dumbbells.

Your habits and environment

If you have increased risk factors such as smoking, alcohol use, or obesity.
A man with his arm around his father's shoulders, standing outside and smiling.

Your medical and family history

Certain conditions# raise your cancer risk. It's important to stay on top of screening.
Two women sitting and smiling at each other.

If you are 3+ years post a cancer diagnosis

Help screening for a second primary cancer with multi-cancer early detection testing.

Searching for signals of cancer in your cells

  • Cancerguard detects signals of cancer within the body.
  • Helps provide insight before symptoms ever appear.
  • Our multiple biomarker approach looks at protein and DNA to detect cancer earlier — when it matters most.
Get actionable results

Negative or positive. That’s it.

Cancer can be intimidating — understanding your results doesn’t have to be. No jargon, just clear insight to help you move forward with confidence.
Calendar icon.

Two weeks to get results

Results typically take just two weeks for our lab to process.
Report icon.

Easy to understand

Your report is specifically designed to help you and your doctor determine your next steps.8
Handshake icon.

Follow up care support

If your results are positive, we'll help guide you through next steps, and may reimburse you for follow-up imaging or other scans if you qualify.

Committed to detecting cancer earlier

A team of Exact Sciences technicians wearing white lab coats and safety goggles.
We launched the Cologuard® test in 2014 — and have been a pioneer in cancer screening innovation for over two decades.
We’ve partnered with respected institutions since 2016 and in most of our major studies of Multi-Cancer Early Detection (MCED) technology.9
With over two decades of experience helping millions navigate life-changing cancer diagnoses, Exact Sciences is redefining cancer screening with Multi-Cancer Early Detection (MCED) testing.

Peace of mind is closer than you think

HSA/FSA eligible
A woman with long white hair and glasses looking up at the sky.
A collage of images showing confident, smiling people.

Footnotes and references

  1. $689 amount reflects self-pay price. FSA/HSA/HRA programs may be a resource you could use to pay as well.
  2. 42% expected reduction in late-stage cancer incidence over a 10-year timeframe with Cancerguard™ compared to standard of care.3
  3. Limitations: Based on modeling data derived from numerous sources including self-reported surveys. Includes assumptions on detectability of certain cancer types. Does not include all cancer types or screening methods.
  4. The percentages shown represent the delta between five year survival rates of local and distant diagnoses.
  5. Check with HSA/FSA administrator to determine eligibility
  6. Patients with the following conditions have a higher risk of cancer and may benefit from expanded screening options like Cancerguard:

    • Type II Diabetes
    • Colorectal polyps
    • Cancer more than 3 years ago
    • Chronic obstructive pulmonary disease (COPD), including emphysema and bronchitis
    • H. pylori
    • Chronic kidney disease (CKD)
    • Rheumatoid arthritis
    • Pancreatitis
    • Hepatitis B or C
    • Gastric ulcer
    • Barrett’s esophagus
    • Crohn’s disease
    • Lupus
    • Liver cirrhosis
    • Family history of cancer
    • Hereditary cancer syndromes

    While the Cancerguard test hasn’t been specifically studied for these conditions, you may still benefit. Talk to your doctor to learn more.

  1. Cancerguard Clinician Brochure. Exact Sciences Corporation. Madison, WI.
  2. Data on file. Cancerguard Cancer Subtype Analysis. Exact Sciences, Madison, WI; September 2025
  3. Data on file. Calculated cancers without USPSTF recommended screening tests. 2025. Medical Affairs, Exact Sciences, Madison, WI.
  4. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer. J Clin. 2025;75(1):10‐45
  5. NORC at the University of Chicago. (2022). Percent of Cancers Detected by Screening in the U.S.‡
  6. American Cancer Society. Cancer Facts & Figures 2025. Atlanta: American Cancer Society; 2025. Last Revised: January 16, 2025
  7. American Cancer Society. Symptoms of Esophageal Cancer | Esophagus Cancer Signs. Published March 20, 2020
  8. Exact Sciences. Cancerguard™ Care Navigation Guide. Published 2025. Accessed July 23, 2025.
  9. Lennon AM, Buchanan AH, Kinde I, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science. 2020;369(6499)

Important Information about the Cancerguard Test

Rx only. Talk to your healthcare provider to determine if this test is right for you.

The Cancerguard™ test is indicated for use in adults ages 50-84 with no known cancer diagnosis in the last three years. It detects alterations in circulating tumor DNA and tumor-associated protein levels which are commonly associated with cancer. The test does not detect all cancers and is not a replacement for existing recommended cancer screening or diagnostic modalities for cancer. Current recommended screening for cancer should also be followed. The test is not indicated for screening of breast and prostate cancer and was not evaluated for the detection of pre-cancerous lesions. Due to the potential for follow-up imaging with IV contrast CT after a positive test result, careful consideration should be given before ordering the Cancerguard test for patients with a history of adverse reactions to iodine based IV contrast or for women who are, may be, or plan to become pregnant. Results should be interpreted in the context of a patient’s medical history, clinical signs, and symptoms. A negative result does not rule out the presence of cancer of any type. A positive Cancerguard™ test result means that the blood test identified a cancer signal that may indicate the presence of cancer. This result alone does not confirm the presence of cancer. Further clinical evaluation by a healthcare provider (which may include blood tests such as complete blood count and comprehensive metabolic panel) and follow-up imaging are needed to locate and confirm a diagnosis of cancer or determine that cancer is not present. While there are no established guidelines for imaging following a positive Cancerguard test result, there is a published follow-up workflow based on expert clinician opinion and results from an exploratory, prospective, interventional study [Kisiel et al Life (Basel) 2024 Jul 24; Lennon et al, Science, 2020]. The proposed workflow in the Kisiel et al publication includes an intravenous-contrast enhanced computed tomography (IV contrast CT of chest, abdomen/pelvis, and soft-tissue neck) and if necessary, positron emission tomography-computed tomography (18F FDG PET-CT) from the skull-base to mid-thigh. Alternative follow-up procedures (e.g. targeted imaging, endoscopic procedures, CT without IV- contrast) may be appropriate in the context of the patient’s medical history and clinical evaluation [Lennon et al, Science, 2020]. False positive and false negative test results can occur.

The Cancerguard test was developed, and the performance characteristics validated by Exact Sciences Laboratories following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. This test has not been cleared or approved by the US Food and Drug Administration. The test is performed at Exact Sciences Laboratories. Exact Sciences Laboratories is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing.